Download PDF
Dtsch Med Wochenschr 2017; 142(22): 1669-1675
DOI: 10.1055/s-0043-108468
Dossier
© Georg Thieme Verlag KG Stuttgart · New York

Zielgerichtete Therapie des Mammakarzinoms

Current Status of Targeted Treatment in Breast Cancer
Katharina Seiffert
,
Barbara Schmalfeldt
,
Volkmar Müller
Further Information

Publication History

Publication Date:
27 October 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Within the last years, significant improvements have been achieved in breast cancer treatment, particularly with the development of targeted therapies. Major progress has been made in identifying the drivers malignant growth in oestrogen-receptor-positive breast cancer and the mechanisms of resistance to endocrine therapy. This progress has translated into several targeted therapies that enhance the efficacy of endocrine therapy; inhibitors of the cyclin-dependent kinases CDK4 and CDK6 like palbociclib and inhibitors of mTOR substantially improve progression-free survival. For patients with HER2-positive disease the addition of Pertuzumab to Trastuzumab in combination with chemotherapy has been a significant improvement in anti-HER2 therapy in early as well as metastatic breast cancer. Evidence-based further line therapy options in the metastatic setting include T-DM1 and in later lines Lapatinib. For triple negative disease the angiogenesis inhibitor Bevacizumab is approved, which increases progression free survival. Immune checkpoint inhibitors, PARP-inhibitors or anti-androgens represent promising strategies, all of which are currently being evaluated in clinical trials. The development of predictive biomarkers to guide targeted therapies is still the subject of research.

Neue Therapieansätze haben die Behandlungsmöglichkeiten des Mammakarzinoms in den letzten Jahren deutlich verbessert. Je nach Subtyp (Hormonrezeptor-positives Mammakarzinom, HER2-positives Mammakarzinom oder triple-negatives Mammakarzinom) können verschiedene zielgerichtete Therapeutika eingesetzt werden. Der folgende Artikel beschreibt die zielgerichtete Therapie des Mammakarzinoms im Frühstadium sowie in der metastasierten Situation.

Schlüsselwörter

Brustkrebs - zielgerichtete Therapie - HER2 - Hormonrezeptor - triple-negativ

Key words

breast cancer - targeted therapy - HER2 - hormone receptor - triple-negative
 

  • Literatur

  • 1 Robertson JF, Come SE, Jones SE. et al. Endocrine treatment options for advanced breast cancer-the role of fulvestrant. Eur J Cancer 2005; 41: 346-356
    CrossrefPubMedGoogle Scholar
  • 2 Aktuelle Empfehlungen zur Diagnostik und Therapie primärer und metastasierter Mammakarzinome der Kommission MAMMA in der AGO e. V. 2017. http://www.ago-online.de last accessed 21st Aug 2017
    PubMedGoogle Scholar
  • 3 Finn RS, Martin M, Rugo HS. et al. Palbociclib and Letrozole in Advanced Breast Cancer. New England Journal of Medicine 2016; 375: 1925-1936
    CrossrefPubMedGoogle Scholar
  • 4 Tiwari SR, Mishra P, Raska P. et al. Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer. Breast Cancer Res Treat 2016; 158: 189-193
    CrossrefPubMedGoogle Scholar
  • 5 Hortobagyi GN, Stemmer SM, Burris HA. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375: 1738-1748
    CrossrefPubMedGoogle Scholar
  • 6 Piccart M, Hortobagyi GN, Campone M. et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger. Ann Oncol 2014; 25: 2357-2362
    CrossrefPubMedGoogle Scholar
  • 7 Slamon DJ, Clark GM, Wong SG. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182
    CrossrefPubMedGoogle Scholar
  • 8 Slamon DJ, Leyland-Jones B, Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792
    CrossrefPubMedGoogle Scholar
  • 9 Kaufman B, Mackey JR, Clemens MR. et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27: 5529-5537
    CrossrefPubMedGoogle Scholar
  • 10 Dahabreh IJ, Linardou H, Siannis F. et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 2008; 13: 620-630
    CrossrefPubMedGoogle Scholar
  • 11 Fisher B, Brown A, Mamounas E. et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-2493
    CrossrefPubMedGoogle Scholar
  • 12 Cortazar P, Zhang L, Untch M. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164-172
    CrossrefPubMedGoogle Scholar
  • 13 Gianni L, Eiermann W, Semiglazov V. et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014; 6: 640-647
    PubMedGoogle Scholar
  • 14 Swain SM, Baselga J, Kim SB. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724-734
    CrossrefPubMedGoogle Scholar
  • 15 Gianni L, Pienkowski T, Im YH. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32
    CrossrefPubMedGoogle Scholar
  • 16 von Minckwitz G. APHINITY trial (BIG 4–11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). J Clin Oncol 2017 35. Abstract LBA500
    PubMedGoogle Scholar
  • 17 Sadeghi S, Olevsky O, Hurvitz SA. Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. Pharmgenomics Pers Med 2014; 7: 329-338
    PubMedGoogle Scholar
  • 18 Verma S, Miles D, Gianni L. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791
    CrossrefPubMedGoogle Scholar
  • 19 Welslau M, Dieras V, Sohn JH. et al. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer 2014; 120: 642-651
    CrossrefPubMedGoogle Scholar
  • 20 Krop IE, Kim SB, Gonzalez-Martin A. et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 689-699
    CrossrefPubMedGoogle Scholar
  • 21 Cameron D, Casey M, Press M. et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-543
    CrossrefPubMedGoogle Scholar
  • 22 Awada A, Colomer R, Inoue K. et al. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. JAMA oncology 2016; 2: 1557-1564
    CrossrefPubMedGoogle Scholar
  • 23 Moulder-Thompson S, Borges VF, Baetz TD. et al. Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+ Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). Clin Cancer Res 2017; 23: 3529-3536
    CrossrefPubMedGoogle Scholar
  • 24 Witzel I, Oliveira-Ferrer L, Pantel K. et al. Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Research 2016; 18: 8
    CrossrefPubMedGoogle Scholar
  • 25 Miller K, Wang M, Gralow J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676
    CrossrefPubMedGoogle Scholar
  • 26 Gray R, Bhattacharya S, Bowden C. et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27: 4966-4972
    CrossrefPubMedGoogle Scholar
  • 27 Robert NJ, Dieras V, Glaspy J. et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-1260
    CrossrefPubMedGoogle Scholar
  • 28 Tutt A, Robson M, Garber JE. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244
    CrossrefPubMedGoogle Scholar
  • 29 Olaparib ASCO. Journal of Clinical Oncology 2017.
    PubMedGoogle Scholar
  • 30 Rugo HS, Olopade OI, DeMichele A. et al. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med 2016; 375: 23-34
    CrossrefPubMedGoogle Scholar
  • 31 Nanda R, Chow LQ, Dees EC. et al. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol 2016; 34: 2460-2467
    CrossrefPubMedGoogle Scholar
  • 32 Emens LA, Braiteh FS, Cassier P. et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Cancer Research 2015 75. Abstract 51-09
    PubMedGoogle Scholar
  • 33 Wang C, Pan B, Zhu H. et al. Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis. Oncotarget 2016; 7: 46482-46491
    CrossrefPubMedGoogle Scholar
  • 34 Gucalp A, Tolaney S, Isakoff SJ. et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res 2013; 19: 5505-5512
    CrossrefPubMedGoogle Scholar
  • 35 Bonnefoi H, Grellety T, Tredan O. et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer T(UCBG 12–1). Ann Oncol 2016; 27: 812-818
    CrossrefPubMedGoogle Scholar